497 related articles for article (PubMed ID: 10760428)
21. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
Singh AK; Lockett MA; Bradley JD
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
[TBL] [Abstract][Full Text] [Related]
22. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer.
Willner J; Baier K; Caragiani E; Tschammler A; Flentje M
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):382-9. PubMed ID: 11872283
[TBL] [Abstract][Full Text] [Related]
23. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung.
Graham MV; Matthews JW; Harms WB; Emami B; Glazer HS; Purdy JA
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(5):1105-17. PubMed ID: 8083080
[TBL] [Abstract][Full Text] [Related]
24. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.
Chao HH; Berman AT; Simone CB; Ciunci C; Gabriel P; Lin H; Both S; Langer C; Lelionis K; Rengan R; Hahn SM; Prabhu K; Fagundes M; Hartsell W; Mick R; Plastaras JP
J Thorac Oncol; 2017 Feb; 12(2):281-292. PubMed ID: 27826034
[TBL] [Abstract][Full Text] [Related]
25. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer.
Armstrong JG; Zelefsky MJ; Leibel SA; Burman C; Han C; Harrison LB; Kutcher GJ; Fuks ZY
Ann Oncol; 1995 Sep; 6(7):693-7. PubMed ID: 8664191
[TBL] [Abstract][Full Text] [Related]
26. Inhomogeneous target-dose distributions: a dimension more for optimization?
De Gersem WR; Derycke S; Colle CO; De Wagter C; De Neve WJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):461-8. PubMed ID: 10760444
[TBL] [Abstract][Full Text] [Related]
27. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F
Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555
[TBL] [Abstract][Full Text] [Related]
28. A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies.
Al-Halabi H; Paetzold P; Sharp GC; Olsen C; Willers H
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):803-10. PubMed ID: 26104934
[TBL] [Abstract][Full Text] [Related]
29. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study.
Zhang X; Li Y; Pan X; Xiaoqiang L; Mohan R; Komaki R; Cox JD; Chang JY
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):357-66. PubMed ID: 19660879
[TBL] [Abstract][Full Text] [Related]
30. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
[TBL] [Abstract][Full Text] [Related]
31. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study.
Marnitz S; Stuschke M; Bohsung J; Moys A; Reng I; Wurm R; Budach V
Strahlenther Onkol; 2002 Nov; 178(11):651-8. PubMed ID: 12426677
[TBL] [Abstract][Full Text] [Related]
32. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
[TBL] [Abstract][Full Text] [Related]
33. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
[TBL] [Abstract][Full Text] [Related]
34. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
[TBL] [Abstract][Full Text] [Related]
35. Non-coplanar beam intensity modulation allows large dose escalation in stage III lung cancer.
Derycke S; Van Duyse B; De Gersem W; De Wagter C; De Neve W
Radiother Oncol; 1997 Dec; 45(3):253-61. PubMed ID: 9426119
[TBL] [Abstract][Full Text] [Related]
36. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
Chang JY; Zhang X; Wang X; Kang Y; Riley B; Bilton S; Mohan R; Komaki R; Cox JD
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1087-96. PubMed ID: 16682145
[TBL] [Abstract][Full Text] [Related]
37. Isotoxic dose escalation in the treatment of lung cancer by means of heterogeneous dose distributions in the presence of respiratory motion.
Baker M; Nielsen M; Hansen O; Jahn JW; Korreman S; Brink C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):849-55. PubMed ID: 21570211
[TBL] [Abstract][Full Text] [Related]
38. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.
Belderbos JS; De Jaeger K; Heemsbergen WD; Seppenwoolde Y; Baas P; Boersma LJ; Lebesque JV
Radiother Oncol; 2003 Feb; 66(2):119-26. PubMed ID: 12648783
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer.
Ling DC; Hess CB; Chen AM; Daly ME
Clin Lung Cancer; 2016 Jan; 17(1):18-23. PubMed ID: 26303127
[TBL] [Abstract][Full Text] [Related]
40. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
